Horan Capital Advisors’s Moderna MRNA Stock Holding History

Horan Capital Advisors’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-100	Closed	-$7K	–	207
2020 Q3	$7K	Buy	+100	New	+$6.97K	﹤0.01%	265

Other funds holding MRNA

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Horan Capital Advisors's MRNA Position: Q4 2020 in Review

Horan Capital Advisors sold out of Moderna (MRNA) in Q4 2020, closing a stake of 100 shares — an estimated $7K sold.

Horan Capital Advisors first reported a position in MRNA in Q3 2020 and held it in 1 quarter. The position peaked at $7K in Q3 2020. 717 funds tracked by Wall St. Rank hold MRNA as of Q4 2020.

Horan Capital Advisors reported no remaining Moderna position as of Q4 2020 after selling out during the quarter.
Horan Capital Advisors sold 100 Moderna shares in Q4 2020, an estimated $7K.
Horan Capital Advisors first reported a position in Moderna in Q3 2020 and held it in 1 quarter.
Horan Capital Advisors's Moderna position peaked at $7K in Q3 2020.
717 funds tracked by Wall St. Rank held Moderna as of Q4 2020.

Based on Horan Capital Advisors's 13F filing for Q4 2020, filed 2 Feb 2021.